机构:[1]Clinical Laboratory,The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China[2]Research Center,The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China[3]Departments of Infection Management, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China河北医科大学第四医院[4]Departments of Biotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China河北医科大学第四医院
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults. Mda-7/IL-24 had been identified as a differentiation inducer of B phenotype lymphoma cells. Previous studies have revealed that knockdown of C-myb also leads to the terminal differentiation of B cell lymphoma. The aim of the present study was to investigate the association between the expression of Mda-7/IL-24 and C-myb, and their prognostic significance for DLBCL patients. The tumor tissues were collected from 72 cases of DLBCL patients and detected with reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry assays. The results showed that, the expression of Mda-7/IL-24 mRNA and protein was lower while the expression of C-myb was higher in DLBCL tissues, compared with the specimens of normal lymph node tissues. Furthermore, C-myb expression was negatively correlated with Mda-7/IL-24 expression at mRNA and protein levels in DLBCL tissues. The expression of Mda-7/IL-24 and C-myb in DLBCL tissues was associated with some clinicopathological parameters such as clinical stage, infiltration in bone marrow, Ki67 expression level in the tumor tissues and overall survival rates. These results indicated that low expression of Mda-7/IL-24, along with high expression of C-myb, are predictor for poor prognosis of DLBC:1 . patients, suggesting that Mda-7/IL-24 and C-myb may be potential targets for clinical treatment of DLBCL.
基金:
The present study was partially supported by the Natural Science Foundation of China (grant no. 81372200), the Natural Science Foundation of China of Hebei Province (grant no. H2015206376) and Health department of Hebei province (grant no. 20160171).
第一作者机构:[1]Clinical Laboratory,The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
共同第一作者:
通讯作者:
通讯机构:[2]Research Center,The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China[*1]Research Center, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, Hebei 050011, P.R. China
推荐引用方式(GB/T 7714):
Ma Ming,Zhao Riyang,Yang Xingxiao,et al.The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma[J].EXPERIMENTAL AND THERAPEUTIC MEDICINE.2018,16(2):649-656.doi:10.3892/etm.2018.6230.
APA:
Ma, Ming,Zhao, Riyang,Yang, Xingxiao,Zhao, Lianmei,Liu, Lihua...&Shan, Baoen.(2018).The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma.EXPERIMENTAL AND THERAPEUTIC MEDICINE,16,(2)
MLA:
Ma, Ming,et al."The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma".EXPERIMENTAL AND THERAPEUTIC MEDICINE 16..2(2018):649-656